Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TAF1 | P21675 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.35 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949386 | 0.94 | BRD4 (0.40) | BRD4PDK2PDK4NPC1RAB9A | |
| SCHEMBL27053465 | 0.90 | BRD4 (0.40) | BRD4 | |
| SCHEMBL1917392 | 0.80 | ADORA3 (0.39) | BRD4ALDH1A1POLBMAPTHPGD | |
| SCHEMBL12963909 | 0.80 | ADORA1 (0.38) | BRD4PDK2PDK4ALDH1A1POLB | |
| SCHEMBL3948904 | 0.78 | PDK2 (0.37) | BRD4PDK2PDK4ALDH1A1POLB | |
| SCHEMBL8219055 | 0.77 | PBK (0.41) | POLBPBK | |
| SCHEMBL3148674 | 0.76 | CCR1 (0.39) | BRD4PDK2PDK4ALDH1A1POLB | |
| SCHEMBL3949234 | 0.75 | TSPO (0.38) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL24683422 | 0.75 | PARP1 (0.41) | PBKPARP1 | |
| SCHEMBL29845257 | 0.75 | PARP1 (0.41) | PBKPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| EP-0598702-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0628557-B1 | Biphenylmethane derivatives, the use of them and pharmacological compositions containing same | EISAI CO LTD (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5506238-A | HYPOTENSIVE AGENT | EISAI CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0420237-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1996-03-06 | — | — | EP | disclosed |
| EP-0628557-A1 | Biphenylmethane derivatives, the use of them and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5328911-A | Cardiovascular disorders, hypotensive agents and congestive heart failure | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0598702-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5298518-A | Biphenylmethane derivative and pharmacological use | EISAI CO., LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0420237-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | BRD4 2678/4885PDK2 3682/4885PDK4 2518/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | BRD4 4497/4885PDK2 3811/4885PDK4 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.